BRPI0509720A - derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina - Google Patents

derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina

Info

Publication number
BRPI0509720A
BRPI0509720A BRPI0509720-7A BRPI0509720A BRPI0509720A BR PI0509720 A BRPI0509720 A BR PI0509720A BR PI0509720 A BRPI0509720 A BR PI0509720A BR PI0509720 A BRPI0509720 A BR PI0509720A
Authority
BR
Brazil
Prior art keywords
alkyl
substituted
antagonist activity
alkanoyl
piperidine
Prior art date
Application number
BRPI0509720-7A
Other languages
English (en)
Inventor
Frans Eduard Janssens
Francois Maria Sommen
Beno T Christian Albert Boeck
Joseph Elisabeth Leenaerts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0509720A publication Critical patent/BRPI0509720A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS DE 4-ALQUIL- E 4-ALCANOIL-PIPERIDINA SUBSTITUìDA E SEU USO COMO ANTAGONISTAS DE NEUROCININA. A presente invenção refere-se a derivados de 4-alquil- e 4-alcanoil-piperidina substituída tendo atividade antagonista de neurocinina, em particular atividade antagonista de NKC~ 1~ e uma atividade antagonista combinada de NK~ 1~/NK~ 3~ composições contendo os mesmos e seu uso como medicamento, em particular para o tratamento e/ou profilaxia de esquizofrenia, êmese, ansiedade e depressão, síndrome do intestino irritável (IBS), distúrbios do ritmo circadiano, pré-eclâmpsia, nocicepção, dor, em particular dor visceral e neuropática, pancreatite, inflamação neurogênica. asma, doença pulmonar obstrutiva crónica (COPD) e distúrbios de micção tal como incontinência urinária. Os compostos de acordo com a invenção podem ser representados pela Fórmula geral (I) e compreendem também os sais de adição de ácido ou de base básica farmaceuticamente aceitáveis, as formas isoméricas dos mesmos, a forma N-óxido dos mesmos e pró-drogas dos mesmos, em que todos os substituintes são definidos como na reivindicação 1.
BRPI0509720-7A 2004-04-08 2005-04-04 derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina BRPI0509720A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101467 2004-04-08
PCT/EP2005/051509 WO2005097774A1 (en) 2004-04-08 2005-04-04 Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists

Publications (1)

Publication Number Publication Date
BRPI0509720A true BRPI0509720A (pt) 2007-09-25

Family

ID=34928945

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509720-7A BRPI0509720A (pt) 2004-04-08 2005-04-04 derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina

Country Status (23)

Country Link
US (1) US20070213346A1 (pt)
EP (1) EP1737838B1 (pt)
JP (1) JP2007532516A (pt)
KR (1) KR20070007347A (pt)
CN (1) CN1938291B (pt)
AR (1) AR048532A1 (pt)
AT (1) ATE396185T1 (pt)
AU (1) AU2005231986B2 (pt)
BR (1) BRPI0509720A (pt)
CA (1) CA2561967A1 (pt)
DE (1) DE602005007002D1 (pt)
EA (1) EA010312B1 (pt)
ES (1) ES2307169T3 (pt)
IL (1) IL178461A0 (pt)
JO (1) JO2525B1 (pt)
MX (1) MXPA06011683A (pt)
MY (1) MY142773A (pt)
NO (1) NO20065022L (pt)
NZ (1) NZ550098A (pt)
PA (1) PA8628901A1 (pt)
TW (1) TWI358298B (pt)
WO (1) WO2005097774A1 (pt)
ZA (1) ZA200608356B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659275B2 (en) * 2005-02-23 2010-02-09 Schering Corporation Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
ES2422718T3 (es) * 2009-04-02 2013-09-13 Merck Patent Gmbh Derivados de piperidina y piperazina como inhibidores de la autotaxina
CN102428069B (zh) 2009-04-02 2014-04-02 盐野义制药株式会社 丙烯酰胺化合物及其用途
JP5806672B2 (ja) * 2009-10-30 2015-11-10 ドメイン・セラピューティクス 新規オキシム誘導体及び代謝型グルタミン酸受容体のアロステリック調節因子としての利用
KR101716099B1 (ko) * 2013-09-12 2017-03-13 에프. 호프만-라 로슈 아게 인돌-카복스아마이드 유도체
RU2743206C2 (ru) 2015-05-18 2021-02-16 Кэнди Терапьютикс Лимитед Двойные антагонисты рецептора нейрокинин-1/нейрокинин-3 для лечения заболеваний, зависимых от половых гормонов
AU2019233606A1 (en) 2018-03-14 2020-09-17 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual NK-1/NK-3 receptor antagonists
ES2963356T3 (es) * 2019-06-12 2024-03-26 Nouryon Chemicals Int Bv Método para aislar ácido carboxílico a partir de una corriente lateral acuosa
JP7336541B2 (ja) 2019-06-12 2023-08-31 ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ 過酸化ジアシルを生成するためのプロセス
HUE063796T2 (hu) 2019-06-12 2024-01-28 Nouryon Chemicals Int Bv Eljárás diacil-peroxidok elõállítására

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW382017B (en) * 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US6642226B2 (en) * 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
US7514424B2 (en) * 2002-12-23 2009-04-07 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists

Also Published As

Publication number Publication date
CA2561967A1 (en) 2005-10-20
JP2007532516A (ja) 2007-11-15
DE602005007002D1 (de) 2008-07-03
TW200603797A (en) 2006-02-01
CN1938291B (zh) 2011-11-16
AU2005231986A1 (en) 2005-10-20
CN1938291A (zh) 2007-03-28
KR20070007347A (ko) 2007-01-15
US20070213346A1 (en) 2007-09-13
EP1737838A1 (en) 2007-01-03
PA8628901A1 (es) 2006-09-08
MXPA06011683A (es) 2006-12-14
ATE396185T1 (de) 2008-06-15
ES2307169T3 (es) 2008-11-16
NZ550098A (en) 2009-10-30
IL178461A0 (en) 2007-02-11
AR048532A1 (es) 2006-05-03
EA200601880A1 (ru) 2007-02-27
WO2005097774A1 (en) 2005-10-20
EP1737838B1 (en) 2008-05-21
AU2005231986B2 (en) 2011-02-24
MY142773A (en) 2010-12-31
EA010312B1 (ru) 2008-08-29
JO2525B1 (en) 2010-03-17
TWI358298B (en) 2012-02-21
NO20065022L (no) 2006-11-03
ZA200608356B (en) 2008-07-30

Similar Documents

Publication Publication Date Title
BRPI0509720A (pt) derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina
TW200604198A (en) Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
MY142090A (en) Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
US11091478B2 (en) Apoptosis-inducing agents
BRPI0608074A2 (pt) derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
BRPI0511722A (pt) 3-amino-1-arilpropilindóis como inibidores da recaptação de monoamina
TR201820559T4 (tr) Azelastin içeren kompozisyonlar ve bunların kullanım metotları.
BR0317658A (pt) Derivados de 1-piperidin-4-il-4-pirrolidin-3-il-piperazina substituìda e seu emprego como antagonistas de neuroquinina
CL43596B (es) Compuestos derivados de pirimidina; composicion farmaceutica; y su uso para tratar o prevenir un trastorno o enfermedad relacionado con la actividad de crth2, tales como asma, rinitis alergica, dermatitis, atopica y conjuntivitis alergica.
BR112021022099A2 (pt) Derivados de amino quinazolina como inibidores de p2x3
NZ591914A (en) Naphthylacetic acids
BR112014013958A2 (pt) ácidos piperidinila naftilacéticos
WO2010091104A8 (en) Glucosylceramide synthase inhibitors
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
AR078552A1 (es) Derivados de feniloxadiazol como agentes inhibidores de las pgds
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
EA200800183A1 (ru) Новые производные индолкарбоксамида, содержащая их фармацевтическая композиция и способ лечения
CL2007002349A1 (es) Compuestos derivados de pirazolo[3,4-b]piridina; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de una enfermedad inflamatoria y/o alergica, tal como epoc, asma y rinitis.
EA200701898A1 (ru) Производные диаза-спиро-[4.4]-нонана в качестве антагонистов нейрокинина (nk1)
DE602005022558D1 (de) Mikroemulsionsformulierungen mit bestimmten substanz p antagonisten
MX2021014116A (es) Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).
MY145168A (en) Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
BR0315762A (pt) Utilização de derivados de ácidos piperazino-sulfónicos como antagonistas ccr1 para o tratamento de fibrose, doença de alzheimer e outras doenças
TH80265B (th) อนุพันธ์ของ 4-แอลคิล- และ 4-แอลคาโนอิล-ไพเพริดีน ที่ได้รับการแทนที่ และการใช้ของมันเป็นแอนทาโกนิสท์ของนิวโรไคนิน

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.